Organon & Co., a global healthcare company specializing in women's health, has announced results from their Phase 2 ELENA proof-of-concept study. The study evaluated the investigational candidate OG-6219, an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor, in patients with endometriosis-related pain. The trial did not meet its primary efficacy endpoint, as OG-6219 failed to demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Consequently, Organon plans to discontinue the clinical development program for OG-6219. The study was a randomized, double-blind, placebo-controlled, global multi-center trial involving pre-menopausal women aged 18 to 49 with surgically diagnosed endometriosis.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。